Bioventus expects 2026 revenue of $590M-$595M while reaffirming adjusted EPS of $0.75-$0.79

What happened: Bioventus (BVS) said it expects 2026 revenue of $590M-$595M and reaffirmed adjusted EPS of $0.75-$0.79, per its Q3 2026 earnings call. Key numbers: 2026 revenue guidance $590M-$595M; adjusted EPS $0.75-$0.79. Why it matters: CEO Robert Claypoole said the previously disclosed strategic process remains active, with advisers assisting as the company evaluates a range of strategic options.

Bioventus (BVS) said it expects 2026 revenue of $590M-$595M and reaffirmed adjusted EPS of $0.75-$0.79, per its Q3 2026 earnings call.

CEO Robert Claypoole said the previously disclosed strategic process remains active, with advisers assisting as the company evaluates a range of strategic options.